Opinion

Video

Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.

Related Videos
A panel of 4 experts on PNH
A panel of 4 experts on PNH
Ryan Jacobs, MD, Atrium Health Levine Cancer Institute
A panel of 4 experts on biosimilars
A panel of 4 experts on CLL
A panel of 4 experts on CLL
A panel of 5 experts on RSV
A panel of 5 experts on RSV
Related Content
CH LogoCenter for Biosimilars Logo